{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:22:26Z","timestamp":1793733746344,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11060-019-03234-8","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T16:03:26Z","timestamp":1561737806000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9470-5890","authenticated-orcid":false,"given":"Victor M.","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Graffeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie J.","family":"Van Gompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"issue":"9679","key":"3234_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/s0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet (London, England) 373(9679):1974\u20131986. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(09)60259-2","journal-title":"Lancet (London, England)"},{"key":"3234_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DG Evans","year":"2009","unstructured":"Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 4:16. \n                    https:\/\/doi.org\/10.1186\/1750-1172-4-16","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3234_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","volume":"11","author":"DG Evans","year":"2009","unstructured":"Evans DG (2009) Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med 11(9):599\u2013610. \n                    https:\/\/doi.org\/10.1097\/GIM.0b013e3181ac9a27","journal-title":"Genet Med"},{"issue":"304","key":"3234_CR4","first-page":"603","volume":"84","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84(304):603\u2013618","journal-title":"Q J Med"},{"issue":"5","key":"3234_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/00006123-199605000-00004","volume":"38","author":"VF Mautner","year":"1996","unstructured":"Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, Pulst SM (1996) The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38(5):880\u2013885; (discussion 885-886)","journal-title":"Neurosurgery"},{"issue":"4","key":"3234_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/neuonc\/nou317","volume":"17","author":"R Dewan","year":"2015","unstructured":"Dewan R, Pemov A, Kim HJ, Morgan KL, Vasquez RA, Chittiboina P, Wang X, Chandrasekharappa SC, Ray-Chaudhury A, Butman JA, Stewart DR, Asthagiri AR (2015) Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro-oncology 17(4):566\u2013573. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nou317","journal-title":"Neuro-oncology"},{"issue":"4","key":"3234_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358\u2013367. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0902579","journal-title":"N Engl J Med"},{"issue":"6","key":"3234_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/coa.12882","volume":"42","author":"SKW Lloyd","year":"2017","unstructured":"Lloyd SKW, King AT, Rutherford SA, Hammerbeck-Ward CL, Freeman SRM, Mawman DJ, O'Driscoll M, Evans DG (2017) Hearing optimisation in neurofibromatosis type 2: a systematic review. Clin Otolaryngol 42(6):1329\u20131337. \n                    https:\/\/doi.org\/10.1111\/coa.12882","journal-title":"Clin Otolaryngol"},{"issue":"1","key":"3234_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","volume":"26","author":"P Caye-Thomasen","year":"2005","unstructured":"Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, Stangerup SE, Thomsen J (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26(1):98\u2013101","journal-title":"Otol Neurotol"},{"issue":"1","key":"3234_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4161\/15384047.2014.972765","volume":"16","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Roberts D, Stankovic KM (2015) Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells. Cancer Biol Ther 16(1):170\u2013175. \n                    https:\/\/doi.org\/10.4161\/15384047.2014.972765","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3234_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11060-007-9336-0","volume":"83","author":"T Uesaka","year":"2007","unstructured":"Uesaka T, Shono T, Suzuki SO, Nakamizo A, Niiro H, Mizoguchi M, Iwaki T, Sasaki T (2007) Expression of VEGF and its receptor genes in intracranial schwannomas. J Neuro-oncology 83(3):259\u2013266. \n                    https:\/\/doi.org\/10.1007\/s11060-007-9336-0","journal-title":"J Neuro-oncology"},{"issue":"9","key":"3234_CR12","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.Can-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E (2010) Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70(9):3483\u20133493. \n                    https:\/\/doi.org\/10.1158\/0008-5472.Can-09-3107","journal-title":"Cancer Res"},{"issue":"2","key":"3234_CR13","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1093\/neuros\/nyx516","volume":"82","author":"JJ Van Gompel","year":"2018","unstructured":"Van Gompel JJ, Agazzi S, Carlson ML, Adewumi DA, Hadjipanayis CG, Uhm JH, Olson JJ (2018) Congress of neurological surgeons systematic review and evidence-based guidelines on emerging therapies for the treatment of patients with vestibular schwannomas. Neurosurgery 82(2):E52\u2013E54. \n                    https:\/\/doi.org\/10.1093\/neuros\/nyx516","journal-title":"Neurosurgery"},{"issue":"1","key":"3234_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-016-2276-9","volume":"131","author":"KA Morris","year":"2017","unstructured":"Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK (2017) Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. J Neuro-oncology 131(1):117\u2013124. \n                    https:\/\/doi.org\/10.1007\/s11060-016-2276-9","journal-title":"J Neuro-oncology"},{"issue":"7","key":"3234_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Althman D (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"1","key":"3234_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","volume":"93","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Halpin C, Blakeley JO, Slattery Iii WH, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker Ii FG (2009) Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neuro-oncology 93(1):61\u201377. \n                    https:\/\/doi.org\/10.1007\/s11060-009-9867-7","journal-title":"J Neuro-oncology"},{"issue":"6","key":"3234_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046\u20131052. \n                    https:\/\/doi.org\/10.1097\/MAO.0b013e31825e73f5","journal-title":"Otol Neurotol"},{"issue":"1","key":"3234_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00129492-200601000-00020","volume":"27","author":"C Halpin","year":"2006","unstructured":"Halpin C, Rauch SD (2006) Using audiometric thresholds and word recognition in a treatment study. Otol Neurotol 27(1):110\u2013116","journal-title":"Otol Neurotol"},{"issue":"3","key":"3234_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s0194-5998(95)70101-x","volume":"113","author":"American Academy of Otolaryngology-Head and Neck Surgery Foundation, inc","year":"1995","unstructured":"American Academy of Otolaryngology-Head and Neck Surgery Foundation, inc (1995) Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). Otolaryngol-Head Neck Surg 113(3):179\u2013180. \n                    https:\/\/doi.org\/10.1016\/s0194-5998(95)70101-x","journal-title":"Otolaryngol-Head Neck Surg"},{"key":"3234_CR20","unstructured":"U.S. Department of Human Health Services (2010) Common terminology criteria for adverse events (CTCAE) v4.0. National Institutes of Health, . \n                    https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5x7.pdf\n                    \n                  . Accessed Accessed Mar 2019"},{"issue":"4","key":"3234_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1214\/aoms\/1177729756","volume":"21","author":"MF Freeman","year":"1950","unstructured":"Freeman MF, Tukey JW (1950) Transformations related to the angular and the square root. Ann Math Stat 21(4):607\u2013611. \n                    https:\/\/doi.org\/10.1214\/aoms\/1177729756","journal-title":"Ann Math Stat"},{"issue":"3","key":"3234_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controll Clin Trials 7(3):177\u2013188","journal-title":"Controll Clin Trials"},{"issue":"7414","key":"3234_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"7454","key":"3234_CR24","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. \n                    https:\/\/doi.org\/10.1136\/bmj.328.7454.1490","journal-title":"BMJ"},{"key":"3234_CR25","unstructured":"Wells G, Shea B, O\u2019connell D, Peterson J, Welch V, Losos M, Tugwell P (2016) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa (ON): Ottawa Hospital Research Institute; 2009. Available in March"},{"issue":"2","key":"3234_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med 23(2):60\u201363. \n                    https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid-Based Med"},{"issue":"4","key":"3234_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088\u20131101","journal-title":"Biometrics"},{"issue":"7109","key":"3234_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"14","key":"3234_CR29","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/jco.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol 34(14):1669\u20131675. \n                    https:\/\/doi.org\/10.1200\/jco.2015.64.3817","journal-title":"J Clin Oncol"},{"issue":"4","key":"3234_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/nop\/npv065","volume":"3","author":"KA Morris","year":"2016","unstructured":"Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, Halliday D, Jena R, Pretorius PM, Evans DG, McCabe MG, Parry A (2016) Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-oncology Pract 3(4):281\u2013289. \n                    https:\/\/doi.org\/10.1093\/nop\/npv065","journal-title":"Neuro-oncology Pract"},{"issue":"12","key":"3234_CR31","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","volume":"272","author":"MC Alanin","year":"2015","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF (2015) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol 272(12):3627\u20133633. \n                    https:\/\/doi.org\/10.1007\/s00405-014-3398-3","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"12","key":"3234_CR32","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1007\/s00405-015-3604-y","volume":"272","author":"S Farschtschi","year":"2015","unstructured":"Farschtschi S, Kollmann P, Dalchow C, Stein A, Mautner V-F (2015) Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol 272(12):3857\u20133860","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"5","key":"3234_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.neuchi.2016.09.004","volume":"64","author":"S Goutagny","year":"2018","unstructured":"Goutagny S, Kalamarides M (2018) Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. Neurochirurgie 64(5):370\u2013374. \n                    https:\/\/doi.org\/10.1016\/j.neuchi.2016.09.004","journal-title":"Neurochirurgie"},{"issue":"2","key":"3234_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","volume":"124","author":"A Hochart","year":"2015","unstructured":"Hochart A, Gaillard V, Baroncini M, Andre N, Vannier J-P, Vinchon M, Dubrulle F, Lejeune J-P, Vincent C, Neve V, Sudour Bonnange H, Bonne NX, Leblond P (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neuro-oncology 124(2):229\u2013236","journal-title":"J Neuro-oncology"},{"issue":"3","key":"3234_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0194599818809085","volume":"160","author":"P Sverak","year":"2019","unstructured":"Sverak P, Adams ME, Haines SJ, Levine SC, Nascene D, Sommer K, Dusenbery K, Huang TC, Moertel C (2019) Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities. Otolaryngol-Head Neck Surg 160(3):526\u2013532. \n                    https:\/\/doi.org\/10.1177\/0194599818809085","journal-title":"Otolaryngol-Head Neck Surg"},{"issue":"8","key":"3234_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"issue":"9","key":"3234_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ, Buter J, Honkoop AH, Boerman D, de Vos FYF, Dinjens WNM, Enting RH, Taphoorn MJB, van den Berkmortel FWPJ, Jansen RLH, Brandsma D, Bromberg JEC, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943\u2013953","journal-title":"Lancet Oncol"},{"issue":"20","key":"3234_CR38","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954\u20131963. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"issue":"5","key":"3234_CR39","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","volume":"261","author":"RE Ferner","year":"2014","unstructured":"Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A, Raymond FL, Durie-Gair J, Hanemann CO, Hornigold R, Axon P, Golding JF (2014) Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol 261(5):963\u2013969. \n                    https:\/\/doi.org\/10.1007\/s00415-014-7303-1","journal-title":"J Neurol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-019-03234-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03234-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T02:30:03Z","timestamp":1593225003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-019-03234-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["3234"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03234-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]},"assertion":[{"value":"28 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no funding sources or conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}